Verastem, Inc.
VSTM
VSTM: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
moreShow VSTM Financials
Recent trades of VSTM by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VSTM's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Therapeutic compositions, combinations, and methods of use Jan. 31, 2023
-
Patent Title: Therapeutic compositions, combinations, and methods of use Jan. 14, 2020
-
Patent Title: Methods and compositions for treating abnormal cell growth Sep. 10, 2019
-
Patent Title: Methods and compositions for treating abnormal cell growth May. 08, 2018
-
Patent Title: Synthesis and use of kinase inhibitors Nov. 29, 2016
-
Patent Title: Oral formulations of kinase inhibitors Jun. 28, 2016
-
Patent Title: Pyrimidine substituted purine compounds as kinase (s) inhibitors Sep. 22, 2015
-
Patent Title: Pyrimidine substituted purine compounds as kinase (s) inhibitors Jun. 17, 2014
-
Patent Title: Pyrimidine derivatives for the treatment of abnormal cell growth May. 13, 2014
-
Patent Title: Pyrimidine substituted purine derivatives Dec. 17, 2013
-
Patent Title: Pyrimidine substituted purine derivatives Aug. 21, 2012
Federal grants, loans, and purchases
Followers on VSTM's company Twitter account
Number of mentions of VSTM in WallStreetBets Daily Discussion
Recent insights relating to VSTM
Recent picks made for VSTM stock on CNBC
ETFs with the largest estimated holdings in VSTM
Flights by private jets registered to VSTM